In a rush for a quick update on selected trial results in #lupus presented at #EULAR2022? Please find my article https://t.co/0XTkPRr6kQ @RheumNow

• SLE trials update: some good and bad news | RheumNow

#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT

#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT

Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa

• https://bit.ly/3GF2mOG

#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf

B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬 FCGR3A-158V: *encodes the allotype ⬆️ affinity for IgG1 *is associated w/ clinical and biological responses in RA and SLE. A new way to stratify pts for anti-CD20 therapy? @Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71

“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow

#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj